A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

  • End date
    Dec 21, 2021
  • participants needed
  • sponsor
    Shandong Cancer Hospital and Institute
Updated on 21 January 2021


Esophageal cancer is the sixth leading cause of cancer death in worldwide. Over the past 2 decades, well-designed clinical trials have documented the clinical benefits of combination of chemotherapy and radiation for localized esophageal cancer, either as primary therapy or in neoadjuvant setting. Paclitaxel, a radiation sensitizer, has important single-agent activity in esophageal cancer. Paclitaxel-based chemoradiation has been the framework for the recent Radiation Therapy Oncology Group (RTOG) trials of nonoperative management of esophageal cancer. Accumulating clinical evidence suggests that Epidermal Growth Factor Receptor (EGFR) represents a viable target in the treatment of esophageal cancer. EGFR expression is associated with poor prognosis. Nimotuzumab binds specifically to EGFR on both normal and tumor cells and competitively inhibits the binding of Epidermal Growth Factor (EGF) and other ligands, such as Transforming Growth Factor- (TGF-). Preclinical models have suggested synergy between nimotuzumab, paclitaxel, cisplatin and radiation. For our phase II study in locally advanced esophageal squamous cell carcinoma (ESCC), the combination of cetuximab and chemoradiotherapy has demonstrated both response and survival benefits. Myara et al reported that nimotuzumab plus concurrent chemoradiation therapy (CCRT) was safe and provided statistically significant objective response (47.8%) and disease control rate (60.9%) in nonresectable ESCC. With all these, the investigators plan to study phase III trial.


The primary endpoint of this study is overall survival, and the primary hypothesis is the experimental arm will improve median survival time (MST) from 18.2 month to 28.5 month. Assuming bilateral = 0.05, statistical power of 80%.Each group requires a minimum of 59 cases. Consider the 20% loss factor.The total sample size is 200 cases.It is 100 cases in each group.

Condition Prosthesis Survival
Treatment Radiotherapy, Placebo, Nimotuzumab, chemoradiotherapy Paclitaxel, chemoradiotherapy Cisplatin
Clinical Study IdentifierNCT02409186
SponsorShandong Cancer Hospital and Institute
Last Modified on21 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 70 yrs?
Gender: Male or Female
Do you have Prosthesis Survival?
Do you have any of these conditions: Do you have Prosthesis Survival??
Signed written informed consent prior to study entry
age18-70 years
Histopathology confirmed primary esophageal squamous cell carcinoma, meet one of the following criteria (AJCC Staging System2009Seventh Edition):Cervical esophageal carcinoma(stage II-III);upper thoracic esophageal cancer or chest esophageal cancer that is unsuitable or refuse surgery (stage II-III)
The existence of measurable lesions (according to Response Evaluation Criteria in Solid Tumors 1.1)
Eastern Cooperative Oncology GroupECOGPerformance status of 0-1
Possible semi-liquid diet
If there is a risk of pregnancy, male and female subjects must be effective contraception during treatment
Normal bone marrow reserve: neutrophil (ANC) count1500/mm3,platelet count100,000 /mm3, hemoglobin5.6mmol/L(9g/dL)
Normal renal function: serum creatinine1.5mg/dl and/or calculated creatinine clearance 60ml/min
Normal hepatic function: bilirubin level1.5ULN, alanine aminotransferase aspartate transaminaseASAT& ALST1.5ULN
Subjects tumor tissue available for the relevant biomarker detection

Exclusion Criteria

Previous chest radiotherapy, systemic chemotherapy, and major esophageal surgery
Concurrent chronic systemic immune therapy, targeted therapy, anti-vascular endothelial growth factorVEGFtherapy or EGFR-pathway targeting therapy not indicated in this study protocol
Multiple primary carcinomas of the esophagus
Pregnancy (confirmed by urine -HCG) or lactation period
Uncontrolled diabetes, hypertension, and severe cardiac or pulmonary disease
There are obvious esophageal ulcers, chest and back more than moderate pain, symptoms of esophageal perforation
Unable to comprehend the study requirements or who are not likely to comply with the study requirements
Patients with distant metastasis
Patients with other malignant disease, except for curable non-melanoma skin cancer, cervical carcinoma in situ or malignant disease cure for5 years
Known grade 3 or 4 allergic reaction to any of the study treatment
Peripheral neuropathy > grade 1
Participation in another clinical study within the past 30 days
Significant disease which, in the investigator's opinion, would exclude the patient from the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note